Treating high-risk people with a rheumatoid arthritis drug could help delay the condition's onset by up to 4 years, new research suggests.

More than 18 million people worldwide suffer from rheumatoid arthritis, including nearly 1.5 million Americans.

One-year treatment with abatacept delays progression to rheumatoid arthritis for up to 4 years among at-risk patients.

South Korea's Hyundai ADM Bio plans to launch global clinical trials of its new drug, Penetrium, for rheumatoid arthritis and ...

People receiving a year of abatacept (Orencia) injections had onset of rheumatoid arthritis postponed by up to four years, ...

If your joints are extra achy at this time of year, you're in good company. Wintery and wet weather can trigger flare-ups for ...

Researchers say following a Mediterranean-style or anti-inflammatory eating pattern could help reduce your chances of ...

You can reduce osteoporosis risk with RA and care for bone health through effective treatments, lifestyle changes, and proper ...

Lower oral microbiome α-diversity was linked to an increased prevalence of RA, with compositional differences in β-diversity found between those with vs without RA.

Early childhood is a key period for immune maturation, yet evidence linking early animal exposures with the development of ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

For the founder of Reclaim Labs, the battle with this condition was not merely a medical hurdle but a life-changing ...